Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-OIC
NCT07477444Phase 2Not yet recruiting
- Sponsor
- UZ Leuven
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of zanidatamab in gastroesophageal adenocarcinoma, sponsored by UZ Leuven. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07477444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477444.